RemeGen’s RC88 shows promising results in Phase I/II study for advanced solid tumors

RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class ... Read More